Base Business Grows 8%: Strong Launches Prompt $400M Revenue Upgrade (GILD Q1 2026 Earnings Call)

By Dr. Graph | Updated on May 9, 2026 | earnings

Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.

Gilead Sciences delivered robust first-quarter results characterized by significant growth in its core virology business and rapid uptake of newly launched therapies. The financial outperformance provides management with the flexibility to absorb major strategic acquisitions while upgrading top-line expectations for the year.

Base Business Grows 8% as HIV Prevention Surges

A surge in HIV prevention therapies and strategic oncology acquisitions are fundamentally accelerating Gilead Sciences' commercial momentum, driving an 8% year-over-year increase in base product sales to $6.8 billion. This top-line expansion was anchored by the core HIV franchise, which generated $5.0 billion in revenue as demand for modern treatment regimens accelerated.

Chief Financial Officer Andrew Dickinson reported a non-GAAP diluted earnings per share of $2.03. This profitability metric demonstrates robust commercial execution and disciplined expense management across the organization.

Strong Launch Trajectories Prompt Revenue Upgrade

Management raised full-year expectations based on the rapid uptake of new therapies. Total product sales guidance increased by $400 million to a new upper bound of $30.4 billion. This upgrade reflects growing confidence in the HIV prevention market, where the revenue target for the twice-yearly injectable Yes2Go was elevated to $1 billion.

Dickinson noted that excluding transaction-related impacts, the projected non-GAAP earnings per share remains strong between $8.45 and $8.85. The company's ability to absorb incremental expenses while raising top-line targets illustrates a flexible and resilient operating model.

Strategic Acquisitions Expand Oncology Capabilities

The company advanced its external innovation strategy by closing the Arcellx acquisition while finalizing the Tubulis transaction. The Tubulis deal brings the clinical-stage asset TUB-40, an antibody-drug conjugate with promising potential in platinum-resistant ovarian cancer. In the commercial oncology segment, Trodelvy sales surged 37% year-over-year to $402 million as physician confidence grew.

Chief Medical Officer Dietmar Berger emphasized that the pipeline now features 47 clinical programs. This extensive portfolio spans diverse approaches to address challenging autoimmune diseases and complex cancers, setting the foundation for long-term clinical momentum.

Yes2Go Persistency Reassures Market Confidence

Analysts questioned the persistency rates for the new long-acting HIV prevention injectable. Chief Commercial Officer Johanna Mercier explained that early patient return rates for the second dose have been highly encouraging.

She indicated that health care professionals are finding subsequent injections easier to administer, which improves the overall patient experience. Mercier observed, "Although it is still early, we expect Yes2Go persistency to be the highest in the HIV prevention category."

Frequently Asked Questions

What drove the increased full-year revenue guidance?

Chief Financial Officer Andrew Dickinson cited revenue outperformance in the first quarter and expected momentum through the rest of the year, particularly increasing the Yes2Go sales target to $1 billion.

How is the Tubulis acquisition expanding the oncology pipeline?

Chief Medical Officer Dietmar Berger stated that the acquisition brings TUB-40, a potential first-in-class antibody-drug conjugate with transformative potential in platinum-resistant ovarian cancer without requiring biomarker selection.

When will the newly acquired anitocel therapy generate revenue?

Chief Commercial Officer Johanna Mercier indicated that following a late December regulatory action date and site activation, the company expects revenue from the multiple myeloma therapy to begin in early 2027.